Skip to main content
OpenTrials

Clinical trial condition

Urothelial Carcinoma

Explore clinical trials studying Urothelial Carcinoma. Study availability and eligibility vary by location and protocol.

243 public trials 72 recruiting studies
Refine in advanced search Browse all conditions

Urothelial Carcinoma trial results

Completed

A Study of Atezolizumab (Tecentriq®) in Ministry of Food and Drug Safety (MFDS)-Approved Indication(s)

NCT03232593

Conditions
Adenocarcinoma, Breast Diseases, Breast Neoplasms, +27 more
Locations
  • Dongnam Inst.of Radiological & Medical Sciences Busan, South Korea
  • Inje University Busan Paik Hospital Busan, South Korea
  • Inje university Haeundae Paik Hospital Busan, South Korea
  • Dong-A University Hospital Busan, South Korea
View all 56 locations
View Trial Details
Completed

Phase 2 Study of Docetaxel +/- OGX-427 in Patients With Relapsed or Refractory Metastatic Bladder Cancer

NCT01780545

Conditions
Bladder Cancer, Carcinoma, Carcinoma, Transitional Cell, +14 more
Locations
  • University of Alabama Hematology Oncology Clinic at Medical West Birmingham, Alabama, United States
  • City of Hope: Duarte Duarte, California, United States
  • City of Hope: Antelope Valley Lancaster, California, United States
  • USC: Norris Comprehensive Cancer Center Los Angeles, California, United States
View all 35 locations
View Trial Details
Completed

First-Line Gemcitabine, Cisplatin + Ipilimumab for Metastatic Urothelial Carcinoma

NCT01524991

Conditions
Carcinoma, Carcinoma, Transitional Cell, Neoplasms, +3 more
Locations
  • City of Hope: Duarte Duarte, California, United States
  • IU Health Goshen Hospital Goshen, Indiana, United States
  • Indiana University Melvin & Bren Simon Cancer Center Indianapolis, Indiana, United States
  • IU Health Central Indiana Cancer Centers Indianapolis, Indiana, United States
View Trial Details
Completed

Maintenance With Niraparib In Patients With Advanced Urothelial Cancer After 1st-line Platinum-based Chemotherapy

NCT03945084

Conditions
Carcinoma, Carcinoma, Transitional Cell, Neoplasms, +3 more
Locations
  • Azienda Sanitaria Locale CN2 - Alba e Bra Alba, Italy
  • Azienda USL Toscana Sud Est, Ospedale San Donato Arezzo, Italy
  • Istituto Tumori Giovanni Paolo II - IRCCS Bari, Italy
  • Presidio Ospedaliero Senatore A.Perrino Brindisi, Italy
View all 20 locations
View Trial Details
Completed

Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine

NCT03633110

Conditions
Adenocarcinoma, Bronchial Neoplasms, Carcinoma, +39 more
Locations
  • UC San Diego Moores Cancer Center La Jolla, California, United States
  • John Wayne Cancer Institute - Providence Saint John's Health Center Santa Monica, California, United States
  • University of Colorado, Anschutz Cancer Pavilion Aurora, Colorado, United States
  • Dana-Farber Cancer Institute Boston, Massachusetts, United States
View Trial Details
Completed

A Dose Escalation Study Of PF-06801591 In Melanoma, Head And Neck Cancer (SCCHN), Ovarian, Sarcoma, Non-Small Cell Lung Cancer, Urothelial Carcinoma or Other Solid Tumors

NCT02573259

Conditions
Carcinoma, Carcinoma, Transitional Cell, Melanoma, +21 more
Locations
  • Clinical Research Unit Los Angeles, California, United States
  • Ronald Reagan Medical Center, Department of Radiological Sciences Los Angeles, California, United States
  • Ronald Reagan UCLA Medical Center, Drug Information Center Los Angeles, California, United States
  • UCLA Hematology & Oncology Clinic Los Angeles, California, United States
View all 67 locations
View Trial Details

Related conditions